Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor

The outcomes of stem cell transplant for patients with blast crisis chronic myeloid leukemia pretreated with tyrosine kinase inhibitors

Posted by on Aug 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of stem cell transplant in patients with blast crisis chronic myeloid leukemia who were pre-treated with tyrosine kinase inhibitors.   This study concluded that the survival of these patients was strongly dependent on pretransplant remission status.  Some background...

Read More

Outcomes od BCR-ABL mutated chronic myeloid leukemia patients who have failed tyrosine kinase inhibitors

Posted by on Aug 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the frequency of BCR-ABL kinase domain mutation detection and its prognostic significance in patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs).  This study concluded that early mutation detection and use of 2nd and...

Read More

Heart-related side effects of tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Mar 31, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of cardiovascular (heart and blood vessel) side effects in patients with chronic myeloid leukemia who were treated with tyrosine kinase inhibitors. This study concluded that these side effects were more frequent in this group of patients. Some background Cardiovascular events (CVE) have been...

Read More

Symptom burden for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Posted by on Oct 30, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the symptom burden on patients with chronic phase chronic myeloid leukemia (CP-CML) who were treated with second or third generation tyrosine kinase inhibitors. This study concluded that the side effects of this treatment may affect the quality of life for these patients. Some background Chronic myeloid...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Posted by on Aug 21, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...

Read More

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Posted by on Aug 18, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...

Read More

The effect of other conditions on ibrutinib treatment of CLL

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...

Read More

Can tyrosine kinase inhibitors influence survival rates in chronic phase chronic myeloid leukemia?

Posted by on Jun 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...

Read More